The device introduces real-time flow technology, a non-invasive method designed to continually monitor the flow rate of fluids within the system
Gyros Protein Technologies has launched the PurePep Sonata+, a mid-pilot scale peptide synthesiser positioned as a direct upgrade to the company’s Sonata XT.
The device introduces real-time flow technology, a non-invasive method designed to continually monitor the flow rate of fluids within the system, which enables accurate and precise fluid transfers for a range of viscosities. The need to calibrate is thereby minimised, the manufacturer claims, and workflows that previously required one day for fluid calibration are significantly shortened. The company’s proprietary valve block system is also integrated to mitigate cross-contamination. The system’s software platform, designed for 21 CFR Part 11 compliance, facilitates the transition from the bench scale PurePep Chorus to mid-pilot scale.
Mark Vossenaar, VP, General Manager, Gyros Protein Technologies, commented: “The introduction of PurePep Sonata+ represents our commitment to building on the Company’s proven expertise and heritage to implement innovative technologies that continue to improve performance. With new intuitive software and hardware improvements, PurePep Sonata+ is much easier to operate and offers even greater reliability than Sonata XT, reinforcing confidence in our peptide synthesizers for research and development.”
A beta site scientist added: “We beta-tested PurePep Sonata+ and found the platform easy-to-use whilst yielding robust, reliable results. The reduced calibration is a great improvement and, with software that allows us to program new syntheses as we run another, it is an invaluable asset for delivering high purity peptides more quickly.”